Functional Phage Display for Enzyme Inhibitor Discovery

Service Overview

A phage-display binding hit is only useful for inhibitor discovery if it produces a reproducible change in enzyme activity. Alongside our Functional Target Screening by Phage Display Services, Creative Biolabs connects phage selection with functional testing so candidates can be evaluated as binders, inhibitors, and, when needed, mechanism-focused leads.

We support active-site or substrate-recognition competition, allosteric modulation, exosite binding, and broader enzyme-ligand discovery. Project design can incorporate target state, substrate and cofactor conditions, related-enzyme controls, library format, and the level of evidence required at handoff.

Projects can stop after candidate triage or extend through concentration-response testing, selectivity studies, and kinetic follow-up. Keeping enrichment, binding, inhibition, selectivity, and mechanism as separate evidence layers makes the final dataset easier to interpret and use downstream.

Phage selection and counterselection

Hit sequencing and family prioritization

Direct binding confirmation

Catalytic activity screening

Concentration-response analysis

Selectivity testing

Kinetic or mechanism-focused follow-up

Diagram of Enzyme Inhibitor Screening with Phage Display. (Creative Biolabs Original)

Start with the Type of Inhibition You Want to Discover

Enzymes can be modulated through several interaction surfaces, so the most useful selection design depends on the surface and mechanism relevant to the program. A project seeking substrate-site competition may benefit from competition-based selection or state-specific target presentation, whereas a search for allosteric modulators may deliberately avoid restricting the screen to the active site. For enzymes with regulatory exosites, protein-protein interaction surfaces can be as important as the catalytic pocket.

Discovery Route	What the Screen Is Trying to Find	Functional Evidence Needed
Active-site or substrate-site competition	Candidates that recognize or sterically influence the catalytic or substrate-binding region.	Activity change plus competition or kinetic evidence consistent with the proposed mode of inhibition.
Allosteric inhibition	Binders that alter catalysis through a distal regulatory surface.	Concentration-response activity data plus follow-up showing that the effect is not explained by simple substrate competition.
Exosite or interaction-dependent inhibition	Ligands that perturb substrate recruitment, cofactor binding, or a regulatory protein interaction.	Activity or interaction assay matched to the relevant partner or step.
General enzyme ligand discovery	Sequence-defined binders for subsequent functional triage or structural studies.	Independent binding first; catalytic testing only if inhibition is part of the research goal.

Treat the Activity Assay as Part of the Screening Strategy

Because functional confirmation can become the limiting step after a successful phage selection, we assess assay readiness early. Enzyme construct, catalytic state, substrate/cofactor conditions, reaction window, buffer, and detection chemistry are reviewed so selected candidates can be tested under interpretable conditions.

We also design controls around common false-positive mechanisms, including reporter interference, coupled-enzyme effects, aggregation, nonspecific denaturation, substrate depletion, and enzyme instability. Orthogonal readouts can be added when they materially improve confidence in the result.

When available, a reference inhibitor is used to benchmark assay performance and dynamic range rather than to imply that new phage-derived candidates will share the same potency or mechanism.

Choose the Library and Target Presentation Together

Peptide libraries are well suited to compact grooves, exosites, and interaction motifs that can later be synthesized directly. Antibody-fragment libraries offer larger recognition surfaces and can be useful when high target specificity is important. Protein-fragment or cDNA libraries may be considered when protein-derived interaction regions are the biological focus. The target can be presented as a purified protein, domain, complex, or captured preparation according to the enzyme and the controls that need to be built into selection.

We choose counterselection to answer a specific selectivity question rather than treating it as a generic step. Closely related enzymes, inactive variants, homologous domains, tags, carriers, or capture surfaces can reveal whether enrichment follows the intended enzyme feature. For family-selective programs, the most informative counter-panel usually reflects sequence homology, catalytic mechanism, substrate preference, and the intended downstream application.

Our Enzyme Inhibitor Discovery Workflow

01
Define the Inhibition Strategy
Define the inhibition mode, enzyme state, candidate format, and assay conditions needed for functional confirmation.
02
Select and Counterselect the Library
Combine positive selection with targeted depletion against tags, carriers, related enzymes, inactive states, or other non-informative binders.
03
Prioritize and Confirm Binding Hits
Track enrichment and sequence families, then reconfirm prioritized candidates under target-relevant binding conditions.
04
Measure Functional Inhibition
Evaluate prioritized candidates across a concentration series using appropriate reaction and assay controls.
05
Assess Selectivity and Mechanism
Add related-enzyme comparisons, kinetic studies, or competition experiments when these data are relevant to the downstream decision.

Project Inputs and Deliverables

To scope the project, we typically review the enzyme sequence or construct, catalytic state, substrate/cofactor requirements, current activity assay, known inhibitors or controls, relevant related enzymes, preferred ligand format, and the evidence level needed for the next decision.

You do not need every element fully established before starting. If the catalytic assay is still under development, we can first assess feasibility and define conditions for an interpretable functional readout before committing to deeper inhibitor characterization.

Depending on project scope and the evidence needed for the next decision, the final dataset may include the following outputs. Not every output is required or included in every project.

Candidate & Sequence Outputs

Selection and Binding

Enriched phage pools
Clone sequencing or NGS data
Prioritized sequence families
Independent binding results

Functional Outputs

Activity and Mechanism

Concentration-response curves
Apparent inhibition values under defined assay conditions
Selectivity comparisons
Kinetic or competition data

The scope can be tailored to the decision you need to make: identify binding candidates, confirm functional inhibition, compare selectivity, or advance selected hits into kinetic and mechanism-focused studies.

From an Apparent IC50 to a Mechanistic Hypothesis

An apparent IC50 is interpreted in the context of the assay conditions used to generate it. Enzyme and substrate concentration, preincubation, reaction time, cofactor state, and assay geometry can all shift the value, so we report these conditions with the activity data rather than treating a single IC50 as a universal property or binding constant.

When mechanism matters, follow-up can include initial-rate measurements across substrate and inhibitor matrices, competition with known ligands, or another model appropriate to the enzyme system. Mechanistic assignments are made only when the data support them.

Evidence Layer	Example Readout	What It Supports
Enrichment	Round-level recovery, sequence-family convergence, NGS trends	Prioritized candidates for independent enzyme-binding confirmation.
Independent binding	ELISA, SPR/BLI, pull-down, or another suitable method	Direct recognition under the tested conditions.
Functional inhibition	Concentration-response catalytic assay	Reduced activity in a defined reaction system.
Selectivity	Related-enzyme or homolog panel	Discrimination within the tested comparison set.
Mechanism	Kinetic series, competition, engagement, or structural follow-up	A more specific hypothesis for how enzyme activity is altered.

Published Data

Binding and inhibition of SIRT2 by phage-selected peptide-derived ligands, showing SIRT2 binding, sirtuin selectivity, concentration-response inhibition, and predicted protein-ligand interactions. (OA Literature) — Fig.1 Binding and inhibition of human sirtuins by synthetic ligands derived from selected peptides.

Active-Site-Directed Phage Selection Demonstrates a Route from Binding to Functional Ligands

Tharp and colleagues developed an active-site-directed ligand-evolution approach for phage display using an amber-encoded chemical strategy. Their work showed that selection can be biased toward ligands engaging a defined catalytic region rather than relying only on conventional affinity enrichment. It provides a useful example of aligning target state and selection chemistry with a functional hypothesis, while also showing that specialized reactive chemistries require method-specific validation.

The broader lesson for enzyme inhibitor discovery extends beyond any single chemistry: define the catalytic question before selection, then confirm activity independently after enrichment. Creative Biolabs applies the same evidence logic to conventional peptide or antibody-fragment programs, using project-specific activity assays, counterselection, and kinetic follow-up when warranted.

Frequently Asked Questions

Can a phage-display binding hit be called an enzyme inhibitor?

No. Binding establishes recognition of the enzyme under the tested conditions, but it does not show that catalysis is altered. We classify a candidate as inhibitory only after it produces a reproducible activity decrease in a suitable catalytic assay, with controls that exclude signal interference, nonspecific denaturation, aggregation, or other assay artifacts.

Do you need an established enzyme assay before phage selection begins?

An established assay is strongly preferred when inhibition is the project endpoint because it defines what functional success will look like after selection. If the assay is not ready, we can still discuss the discovery strategy, but assay feasibility should be addressed early. Otherwise, the project may yield strong binders that cannot be ranked reliably for functional inhibition.

Is IC50 enough to determine the mechanism of inhibition?

Usually not. IC50 is an apparent value that depends on assay conditions and can shift with substrate concentration, enzyme concentration, preincubation, cofactors, and reaction timing. Mechanistic classification generally requires a richer kinetic or competition design, often including multiple substrate and inhibitor concentrations and an appropriate model. We recommend that level of follow-up when mechanism information is expected to change candidate selection or downstream research.

How do you test selectivity against related enzymes?

We build the counter-panel around the enzyme family and the intended research use. Closely related homologs, isoforms, inactive variants, or enzymes sharing a catalytic or regulatory domain are often more informative than unrelated proteins. Candidates can be compared during selection, independent binding, functional testing, or at all three stages, depending on when specificity needs to influence the decision.

Can phage display find allosteric inhibitors as well as active-site binders?

Yes. An affinity-based phage screen can recover ligands that bind outside the active site, including candidates with potential allosteric effects. The key challenge is functional interpretation: a distal binder must still be shown to alter catalysis, and any apparent activity effect must be separated from assay interference. When a project intentionally seeks non-orthosteric mechanisms, we avoid over-constraining the selection design.

Can reactive or covalent ligand strategies be included?

Specialized active-site-directed and chemically modified phage-display strategies have been reported in the literature, but they are not interchangeable with a standard peptide screen. Chemistry, library construction, target compatibility, reaction conditions, and analytical confirmation all require project-specific review. We scope these approaches separately rather than implying that covalent engagement has been established through ordinary phage enrichment.

Reference

Tharp, Jeffery M., et al. An amber obligate active site-directed ligand evolution technique for phage display. Nature Communications 11 (2020): 1392. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41467-020-15057-7

Discovery of Enzyme Inhibitors by Phage Display

Discovery of Enzyme Inhibitors by Phage Display

Discovery ofEnzyme Inhibitorsby Phage Display

Service Overview

Start with the Type of Inhibition You Want to Discover

Treat the Activity Assay as Part of the Screening Strategy

Choose the Library and Target Presentation Together

Our Enzyme Inhibitor Discovery Workflow

Define the Inhibition Strategy

Select and Counterselect the Library

Prioritize and Confirm Binding Hits

Measure Functional Inhibition

Assess Selectivity and Mechanism